Autogenous bone is considered to be the current gold standard for bone augmentation; however, only limited amounts of autogenous bone can be harvested at the implantation site. Furthermore this procedure may lead to morbidity problems. As an alternative, a commercially available synthetic bone graft substitute comprising porous biphasic calcium phosphate, in the form of granules, has been on the market since 2004. In this study we report long-term implant survival rate. Keywords: implant survival, bone augmentation, biphasic calcium phosphate